Can Fite Biopharma Ltd

자세한 내용은 Can Fite Biopharma Ltd 회사

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

회사 정보

종목 코드 CANF

회사 이름Can Fite Biopharma Ltd

상장일Sep 22, 2005

CEODr. Pnina Fishman, Ph.D.

직원 수5

유형Ordinary Share

회계 연도 종료Sep 22

주소10 Bareket Street, Kiryat Matalon

도시PETAH TIKVA

증권 거래소Tel Aviv Stock Exchange

국가Israel

우편 번호49170

전화97239241114

웹사이트https://www.canfite.com/

종목 코드 CANF

상장일Sep 22, 2005

CEODr. Pnina Fishman, Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Yaacov Goldman

Independent Director

--

Mr. Guy Regev

Independent Director

--

Dr. Abraham Sartani, M.D.

Independent Director

--

Dr. Ilan Cohen

Chairman of the Board

--

Dr. Pnina Fishman, Ph.D.

Chief Executive Officer, Director

--

Mr. Motti Farbstein

Chief Financial Officer, Chief Operating Officer

--

Dr. Sari Fishman, Ph.D.

Vice President - Business Development

--

Mr. Yoseph Borenstein

Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Yaacov Goldman

Independent Director

--

Mr. Guy Regev

Independent Director

--

Dr. Abraham Sartani, M.D.

Independent Director

--

Dr. Ilan Cohen

Chairman of the Board

--

Dr. Pnina Fishman, Ph.D.

Chief Executive Officer, Director

--

Mr. Motti Farbstein

Chief Financial Officer, Chief Operating Officer

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, Sep 6

주주

주주 유형

주주

비율

Sabby Management, LLC

4.94%

Rhumbline Advisers Ltd. Partnership

0.37%

Abalone Asset Management Ltd.

0.15%

BNP Paribas Securities Corp. North America

0.11%

Two Sigma Investments, LP

0.10%

기타

94.33%

주주

비율

Sabby Management, LLC

4.94%

Rhumbline Advisers Ltd. Partnership

0.37%

Abalone Asset Management Ltd.

0.15%

BNP Paribas Securities Corp. North America

0.11%

Two Sigma Investments, LP

0.10%

기타

94.33%

주주 유형

주주

비율

Investment Advisor/Hedge Fund

4.94%

Investment Advisor

0.65%

Research Firm

0.19%

Hedge Fund

0.10%

기타

94.11%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

29

155.14K

1.06%

-711.63K

2025Q1

30

155.14K

1.17%

-710.63K

2024Q4

28

154.43K

1.51%

-671.86K

2024Q3

26

794.33K

11.46%

+115.72K

2024Q2

26

667.93K

11.77%

+152.94K

2024Q1

24

517.69K

9.97%

+253.94K

2023Q4

29

283.94K

5.78%

+189.77K

2023Q3

28

67.77K

1.66%

-429.92K

2023Q2

28

54.74K

1.34%

-433.22K

2023Q1

31

368.56K

9.03%

+211.26K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Rhumbline Advisers Ltd. Partnership

38.27K

0.29%

+11.39K

+42.37%

Mar 31, 2025

Abalone Asset Management Ltd.

23.81K

0.18%

-16.19K

-40.48%

Jun 30, 2024

BNP Paribas Securities Corp. North America

22.59K

0.17%

-2.60K

-10.32%

Mar 31, 2025

CAPTRUST Financial Advisors

10.63K

0.08%

+10.63K

--

Mar 31, 2025

Morgan Stanley & Co. LLC

23.21K

0.17%

-9.30K

-28.60%

Mar 31, 2025

MainStreet Advisors

3.00K

0.02%

--

Mar 31, 2025

Wells Fargo Advisors

2.70K

0.02%

+200.00

+8.00%

Mar 31, 2025

0.646USD

Can Fite Biopharma Ltd

0.646

개요

회사

금융

분석